US Generic Drug Spending Declines In A New Development – IQVIA Report
Generic drug spending declined in the US by $5.5bn in 2017 after growing in 2013-2016, pointing to the challenging generic drug dynamics in the US. Volume share data on marketed biosimilars shows impact of insurer control.
You may also be interested in...
The US launch of Pfizer's Inflectra has been an early case study for the US biosimilar market, and some biosimilar manufacturers and payers say market access challenges are worrying.
Avalere survey suggests payers are comfortable with covering the biosimilar but not necessarily actively promoting it over Neupogen or other competing brands.
With US generic drug price erosion running at double digits, 2017 is expected to be a challenging year for the generic drug sector. Manufacturers are looking increasingly to complex generics, injectables and biosimilars as an offset, but it's unclear if wins in those areas will be enough to bridge the growth divide.